Dataset Information

Electroanalysis Applied to Compatibility and Stability Assays of Drugs: Carvedilol Study Case.

ABSTRACT: Carvedilol (CRV) is a non-selective blocker of ? and ? adrenergic receptors, which has been extensively used for the treatment of hypertension and congestive heart failure. Owing to its poor biopharmaceutical properties, CRV has been incorporated into different types of drug delivery systems and this necessitates the importance of investigating their compatibility and stability. In this sense, we have investigated the applicability of several electroanalytical tools to assess CRV compatibility with lipid excipients. Voltammetric and electrochemical impedance spectroscopy techniques were used to evaluate the redox behavior of CRV and lipid excipients. Results showed that Plurol® isostearic, liquid excipient, and stearic acid presented the greatest anode peak potential variation, and these were considered suitable excipients for CRV formulation. CRV showed the highest stability at room temperature and at 50 °C when mixed with stearic acid (7% w/w). The results also provided evidence that electrochemical methods might be feasible to complement standard stability/compatibility studies related to redox reactions.

SUBMITTER: de Carvalho MF

PROVIDER: S-EPMC7243106 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Electroanalysis Applied to Compatibility and Stability Assays of Drugs: Carvedilol Study Case.

de Carvalho Murilo Ferreira MF Garcia Luane Ferreira LF de Macedo Isaac Yves Lopes IYL Marreto Ricardo Neves RN de Oliveira Mayk Teles MT do Couto Renê Oliveira RO da Cunha Carlos Eduardo Peixoto CEP de Siqueira Leite Karla Carneiro KC Rezende Kênnia Rocha KR Machado Fabio Bahls FB Somerset Vernon V Gil Eric de Souza ES

Pharmaceuticals (Basel, Switzerland) 20200417 4

Carvedilol (CRV) is a non-selective blocker of α and β adrenergic receptors, which has been extensively used for the treatment of hypertension and congestive heart failure. Owing to its poor biopharmaceutical properties, CRV has been incorporated into different types of drug delivery systems and this necessitates the importance of investigating their compatibility and stability. In this sense, we have investigated the applicability of several electroanalytical tools to assess CRV compatibility w ...[more]

PMID: 32316568

Similar Datasets

Project description:Carvedilol (CARV) is a blocker of α- and β- adrenergic receptors, used as an "off-label" treatment for cardiovascular diseases in pediatrics. Currently, there is no marketed pediatric-appropriate CARV liquid formulation, so its development is necessary. Palatability (appreciation of smell, taste, and aftertaste) is a key aspect to be considered during the development of pediatric formulations since only formulations with good palatability also have adequate acceptability in this population. Consequently, the aim of this research was to assess the palatability and acceptability of different CARV formulations using an in vivo taste assessment (ID Number PR103/22) in order to select the highest palatability-rated CARV formulation. The preparation of CARV formulations was based on a reference 1 mg/mL CARV solution, which contains malic acid as a solubilizing agent. Subsequently, sucralose and flavoring agents were added and mixed until complete dissolution to the corresponding formulations. Adult volunteers participated in this study and evaluated the taste and odor of various CARV formulations through a questionnaire and a sensory test. The mean palatability score, measured on a 10-point scale, increased from 1.60 for the unflavored control to 7.65 for the highest-rated flavored formulation. Moreover, the bitterness of the optimized CARV formulation was reduced from 66.67% to 17.86%, and the taste pleasantness was increased from 25/100 to 73/100. This optimized CARV formulation contains a sweetening agent, sucralose, in addition to two flavoring agents at appropriate concentrations for pediatrics. Furthermore, the physicochemical and microbiological stability of the optimized CARV formulation were evaluated for 6 months at 25, 30, and 40 °C, in addition to in-use stability for 15 days at 25 °C, whose results were confirmed. Thus, we successfully developed a palatable CARV liquid solution that contains excipients appropriate for pediatrics and is stable under the studied conditions.

Dataset Information

Electroanalysis Applied to Compatibility and Stability Assays of Drugs: Carvedilol Study Case.

Publications

Electroanalysis Applied to Compatibility and Stability Assays of Drugs: Carvedilol Study Case.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets